We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

R-BIOPHARM

R-Biopharm AG is a biotechnology company that offers innovative products for numerous applications in the area of cli... read more Featured Products: More products

Download Mobile App




Molecular Assay Evaluated for Norovirus Detection

By LabMedica International staff writers
Posted on 03 Jul 2014
A commercial real-time polymerase chain reaction (RT-PCR) assay has been evaluated for the detection of noroviruses for use in a routine diagnostic laboratory. More...


The noroviruses (NoVs), which are now recognized as a major cause of both sporadic cases and outbreaks of gastroenteritis, are single-stranded positive-sense ribonucleic acid (RNA) viruses classified as the genus Norovirus within the family Caliciviridae.

Communicable disease specialists at the Victorian Infectious Diseases Reference Laboratory (Melbourne, Australia) tested 100 fecal specimens positive for NoV by open reading frames (ORF) 1 RT-PCR. A second group comprised of 100 fecal specimens negative for NoV by RT-PCR protocols. A third group comprised of 16 fecal specimens, which were selected as a specificity control to evaluate the assay for cross-reactivity to common fecal viruses other than NoV.

The commercial assay under evaluation was the RIDAGENE norovirus (NoV) real-time polymerase chain reaction assay (R-Biopharm; Darmstadt, Germany). The scientists found that the assay was straightforward to perform. For a run of 50 specimens, the PCR component took about one hour. Thus, with initial fecal processing and subsequent RNA extraction, a result could be obtained in roughly four hours for a run of 50 specimens. The RIDAGENE assay had an overall sensitivity of 98% but was more sensitive for GII than GI NoV and the assay had a specificity of 98%. The assay did not cross react with a number of gastroenteritis viruses including adenovirus, astrovirus, Rotavirus, and Sapovirus.

The author concluded that the RIDAGENE assay proved straightforward to use and time efficient. The assay had good sensitivity and specificity and can be recommended as a valuable detection method for NoV in a diagnostic laboratory. The study was published on the July 2014 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Victorian Infectious Diseases Reference Laboratory 
R-Biopharm



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Immunofluorescence Analyzer
IFA System
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Researchers found that tumor DNA fragments in blood can reveal ongoing prostate cancer growth even when current tests show little change (image credit: Adobe Stock)

Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer

Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.